Humana Inc. Files 8-K with Regulation FD Disclosure

TL;DR

Humana filed an 8-K today - standard disclosure, no major news yet.

AI Summary

On March 5, 2024, Humana Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information that may be of interest to investors. No specific financial transactions or material events were detailed in the provided excerpt, but the filing itself is a standard disclosure mechanism.

Why It Matters

This filing serves as a public notification of material information, ensuring transparency for investors and the market regarding Humana Inc.'s disclosures.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information indicating significant new risks or changes.

Key Numbers

• 001-05975 — Commission File Number (Identifies Humana Inc.'s filing with the SEC)
• 61-0647538 — IRS Employer Identification No. (Tax identification for Humana Inc.)

Key Players & Entities

• Humana Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• March 5, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $14.87 — reaffirm its guidance of approximately $14.87 in diluted earnings per common share ("
• $16.00 — common share ("EPS"), or approximately $16.00 in adjusted earnings per common share (

Filing Documents

• hum-20240305.htm (8-K) — 31KB
• 0000049071-24-000015.txt ( ) — 154KB
• hum-20240305.xsd (EX-101.SCH) — 2KB
• hum-20240305_lab.xml (EX-101.LAB) — 24KB
• hum-20240305_pre.xml (EX-101.PRE) — 12KB
• hum-20240305_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at an industry conference and various other meetings between March 5, 2024 and March 31, 2024. During these meetings, the Company intends to reaffirm its guidance of approximately $14.87 in diluted earnings per common share ("EPS"), or approximately $16.00 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2024 ("FY 2024"). This guidance is consistent with the guidance issued in Humana's press release dated January 25, 2024. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company's website at www.humana.com. The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows: Diluted earnings per common share FY 2024 Guidance GAAP approximately $14.87 Amortization of identifiable intangibles 0.49 Impact of exit of employer group commercial medical products business 0.97 Cumulative net tax impact of non-GAAP adjustments (0.33) Adjusted (non-GAAP) – FY 2024 projected approximately $16.00 Cautionary Statement This Current Report on Form 8-K includes forward-looking statements within the m

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. HUMANA INC. BY: /s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer) Dated: March 5, 2024

View Full Filing

View this 8-K filing on SEC EDGAR